Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Context Therapeutics Inc CNTX

Healthcare
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein... see more

Recent & Breaking News (NDAQ:CNTX)

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

GlobeNewswire November 6, 2024

Context Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswire October 23, 2024

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

GlobeNewswire October 16, 2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

GlobeNewswire September 23, 2024

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

GlobeNewswire September 4, 2024

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

GlobeNewswire August 7, 2024

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

GlobeNewswire August 1, 2024

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

GlobeNewswire July 10, 2024

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

GlobeNewswire May 8, 2024

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

GlobeNewswire May 2, 2024

Context Therapeutics Announces $100 Million Private Placement

GlobeNewswire May 2, 2024

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

GlobeNewswire April 1, 2024

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

GlobeNewswire March 21, 2024

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 9, 2023

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

GlobeNewswire October 31, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire September 27, 2023

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

GlobeNewswire August 9, 2023

Context Therapeutics to Participate in Two August 2023 Investor Conferences

GlobeNewswire August 1, 2023

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

GlobeNewswire May 10, 2023

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Accesswire April 18, 2023